Work

A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with Stage IIIB/IV Non-small Cell Lung Cancer

Year: 2011

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Journal of Thoracic Oncology

DOI: 10.1097/jto.0b013e3182210430

Authors: Thomas E. Stinchcombe, Amy H. Peterman, Carrie B. Lee, Dominic T. Moore, Jennifer L. Beaumont, Daniel S. Bradford, Kamal Bakri, Mark Taylor, Jeffrey M. Crane, Garry Schwartz, Thomas A. Hensing, Edwin McElroy, Harvey B. Niell, Harry D. Harper, Sridhar Pal, Mark A. Socinski

Institutions: University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Charlotte, Northwestern University, Highlands Oncology Group, Cape Fear Valley Health System, Cape Fear Valley Medical Center, Rex Hospital, Carolinas Medical Center, Endeavor Health, Memphis VA Medical Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: Genentech

OpenAlex ID: W2057936937

FWCI: 4.353

Cites: 35

Cited by: 35

Related to: 10